Fig. 2

Administration of iPSC-MSC-EXOs attenuated DIC in mice. A Schematic chart showing the creation of a DIC model and administration of PBS, BM-MSC-EXOs or iPSC-MSC-EXOs. B Representative echocardiographic images were captured on day 35 after DOX treatment in mice treated with PBS, BM-MSC-EXOs or iPSC-MSC-EXOs or control mice. C The LVEF and LVFS were analyzed on Day 0, 7, 14 and 35 in controls or mice with DIC that received PBS, BM-MSC-EXO or iPSC-MSC-EXO treatment. D Representative images of HE staining showing myocardial histological changes in DIC mice treated with PBS, BM-MSC-EXOs and iPSC-MSC-EXOs or control mice. E Quantitative analysis of vacuolization in the heart tissue from DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment or control mice. F Representative images of Sirius red staining of heart sections from DIC mice that received PBS, BM-MSC-EXOs or iPSC-MSC-EXOs treatment and control mice. G Quantitative analysis of cardiac fibrosis in different experimental groups. Data are expressed as mean ± SD. n = 6 mice for each group, ***p < 0.001